CRESCITA THERAPEUTICS ORD - CRRTF STOCK NEWS

Crescita Therapeutics Inc. (CRRTF) reported Q1-F2022 revenue of $4,951K, a 52% increase from Q1-F2021. Manufacturing segment revenue reached a record $3,415K, significantly improving from $692K last year. Gross profit rose to $2,712K, though gross margin fell to 54.8%. Operating expenses increased to $3,088K driven by higher SG&A costs. Adjusted EBITDA decreased to $66K. Cash and cash equivalents improved to $11,742K. The company plans expansion into 35 new countries for Pliaglis and launched a new Obagi Medical product line in Canada, enhancing its portfolio.

Crescita Therapeutics Inc. (TSX: CTX, OTC US: CRRTF) announced CEO Serge Verreault will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 3, 2022, at 10:30 a.m. in Hall A at the Metro Toronto Convention Centre. The conference, occurring on May 2-3, features around 60 leading healthcare companies from Canada. Verreault will outline Crescita’s recent business highlights and growth strategy, with the management team available for one-on-one investor meetings. For more details, visit bloomburton.com/conference.

Crescita Therapeutics reported record Q4 and fiscal 2021 revenues of $5.3M, tripling revenue compared to fiscal 2020. Total revenue for 2021 reached $16.8M, up 7.2% year-over-year, despite a drop in gross profit to $10M. The company expanded Pliaglis licenses to 32 countries and maintained a robust liquidity position of $11.3M. Q4 adjusted EBITDA improved to $1.6M from a loss of $0.4M last year. Crescita aims to grow its market presence amid favorable consumer trends and digital marketing investments.

Crescita Therapeutics Inc. announced the Toronto Stock Exchange's approval for the renewal of its normal course issuer bid (NCIB) to repurchase up to 1,000,000 common shares, approximately 5.3% of its public float, over the next 12 months. The company aims to start purchases on December 17, 2021, and the NCIB will conclude on December 16, 2022. Purchases will adhere to trading regulations, with a daily maximum of 3,770 shares. The prior NCIB, active from November 30, 2020, to November 29, 2021, resulted in the acquisition of 135,824 shares at an average price of $0.68.

Crescita Therapeutics Inc. (TSX: CTX, OTC: CRRTF) has entered into an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC for its product Pliaglis. This agreement covers eight countries in Central Eastern Europe and includes an upfront payment of €0.65 million (CAD $0.94 million), along with potential sales and regulatory milestone payments. Egis plans to launch Pliaglis in Poland in early 2023, further expanding Crescita's product presence, which is now licensed in 40 countries.

Crescita Therapeutics Inc. (CRRTF) reported a significant decline in Q3-F2021 revenues, totaling $2,993, down from $7,301 in Q3-F2020, primarily due to a non-recurring licensing agreement impact. Gross profit also fell to $1,525 from $6,129. Operating expenses increased slightly to $2,385. The company announced a licensing agreement for Pliaglis in 15 new countries, acquired a minority stake in The Best You, and amended its credit facility to increase available capital. Additionally, Deborah Shannon-Trudeau was appointed to the board, bringing over 30 years of experience.

Crescita Therapeutics (TSX: CTX, OTC US: CRRTF) has announced an exclusive distribution agreement with Obagi Cosmeceuticals to market the Obagi Medical product line in Canada. This partnership aims to leverage Crescita's established network to promote innovative skincare solutions targeting aging, hyperpigmentation, and skin texture improvement. Both companies express optimism about the collaboration, highlighting Crescita's strong reputation in the Canadian aesthetic market and Obagi's extensive global presence.

Crescita Therapeutics Inc. (CRRTF) has acquired a minority interest in Akyucorp Ltd. d/b/a The Best You, which operates six medical aesthetic clinics in Ontario. This investment involves issuing 470,128 common shares at $0.70 each. Additionally, Crescita will provide a secured convertible promissory note of up to C$1.25M to support The Best You's growth. This partnership aims to enhance sales of Crescita’s aesthetic brands, capitalize on the growing medical aesthetics market, and gain valuable consumer insights, ultimately driving future product development.

Crescita Therapeutics Inc. (OTC US: CRRTF) has entered into an exclusive commercialization agreement with STADA MENA for its topical anesthetic cream, Pliaglis^®, in 15 countries across the Middle East and North Africa (MENA). This partnership allows STADA to commercialize Pliaglis while Crescita will supply the product and provide regulatory support. The agreement marks Crescita's success in licensing Pliaglis in 32 countries, with expectations of increased recurring revenue starting in 2024. Pliaglis, a lidocaine and tetracaine combination, offers effective local analgesia for dermatological procedures.